Wen Hao Neo

Wen Hao Neo

Auto-generated profile, based on publicly available information

Wen Hao Neo

Cancer Research UK Stem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2015 in Nature Immunology
Verified
Journal Article
Closed access
MGMerry Gunawan
Merry Gunawan
NVNandini Venkatesan
Nandini Venkatesan
JLJia Tong Loh
Jia Tong Loh
JWJong Fu Wong
Jong Fu Wong
HBHeidi Berger
Heidi Berger
ISI-Hsin Su
I-Hsin Su

1 July 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
WNWen Hao Neo
Wen Hao Neo
KYKaren Yap
Karen Yap
SLSuet Hoay Lee
Suet Hoay Lee
LLLiang Sheng Looi
Liang Sheng Looi
PKPiyush Khandelia
Piyush Khandelia
ISI-Hsin Su
I-Hsin Su
Polycomb group protein Ezh2 is a histone H3 Lys-27 histone methyltransferase orchestrating an extensive epigenetic regulatory program. Several nervous system-specific genes are known to be repressed by Ezh2 in stem cells and derepressed during neuronal differentiation. However, the molecular mechanisms underlying this regulation remain poorly understood. Here we show that Ezh2 levels are dampened during neuronal differentiation by brain-enriched microRNA miR-124. Expression of miR-124 in a neuroblastoma cells line was sufficient to up-regulate a significant fraction of nervous system-specific Ezh2 target genes. On the other hand, naturally elevated expression of miR-124 in embryonic carcinoma cells undergoing neuronal differentiation correlated with down-regulation of Ezh2 levels. Importantly, overexpression of Ezh2 mRNA with a 3′-untranslated region (3′-UTR) lacking a functional miR-124 binding site, but not with the wild-type Ezh2 3′-UTR, hampered neuronal and promoted astrocyte-specific differentiation in P19 and embryonic mouse neural stem cells. Overall, our results uncover a molecular mechanism that allows miR-124 to balance the choice between alternative differentiation possibilities through fine-tuning the expression of a critical epigenetic regulator.

20 January 2022 in Blood
Verified
Journal Article
Open access
PDF file
MFMuhammad Zaki Hidayatullah Fadlullah
Muhammad Zaki Hidayatullah Fadlullah
WNWen Hao Neo
Wen Hao Neo
MLMichael Lie-A-Ling
Michael Lie-A-Ling
RTRoshana Thambyrajah
Roshana Thambyrajah
RPRahima Patel
Rahima Patel
GLGeorges Lacaud
Georges Lacaud
In vitro generation and expansion of hematopoietic stem cells (HSCs) holds great promise for the treatment of any ailment that relies on bone marrow or blood transplantation. To achieve this, it is essential to resolve the molecular and cellular pathways that govern HSC formation in the embryo. HSCs first emerge in the aorta-gonad-mesonephros (AGM) region, where a rare subset of endothelial cells, hemogenic endothelium (HE), undergoes an endothelial-to-hematopoietic transition (EHT). Here, we present full-length single-cell RNA sequencing (scRNA-seq) of the EHT process with a focus on HE and dorsal aorta niche cells. By using Runx1b and Gfi1/1b transgenic reporter mouse models to isolate HE, we uncovered that the pre-HE to HE continuum is specifically marked by angiotensin-I converting enzyme (ACE) expression. We established that HE cells begin to enter the cell cycle near the time of EHT initiation when their morphology still resembles endothelial cells. We further demonstrated that RUNX1 AGM niche cells consist of vascular smooth muscle cells and PDGFRa+ mesenchymal cells and can functionally support hematopoiesis. Overall, our study provides new insights into HE differentiation toward HSC and the role of AGM RUNX1+ niche cells in this process. Our expansive scRNA-seq datasets represents a powerful resource to investigate these processes further.

1 February 2018 in Cancer Cell
Verified
Journal Article
Closed access
CBChristopher A.G. Booth
Christopher A.G. Booth
NBNikolaos Barkas
Nikolaos Barkas
WNWen Hao Neo
Wen Hao Neo
HBHanane Boukarabila
Hanane Boukarabila
Elizabeth Jane SoilleuxElizabeth Jane Soilleux
Elizabeth Jane Soilleux
AMAdam J. Mead
Adam J. Mead

21 June 2017 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
AMAdam J. Mead
Adam J. Mead
WNWen Hao Neo
Wen Hao Neo
NBNikolaos Barkas
Nikolaos Barkas
SMSahoko Matsuoka
Sahoko Matsuoka
Alice GiustacchiniAlice Giustacchini
Alice Giustacchini
SJSten Eirik W. Jacobsen
Sten Eirik W. Jacobsen
Although previous studies suggested that the expression of FMS-like tyrosine kinase 3 (Flt3) initiates downstream of mouse hematopoietic stem cells (HSCs), FLT3 internal tandem duplications (FLT3 ITDs) have recently been suggested to intrinsically suppress HSCs. Herein, single-cell interrogation found Flt3 mRNA expression to be absent in the large majority of phenotypic HSCs, with a strong negative correlation between Flt3 and HSC-associated gene expression. Flt3-ITD knock-in mice showed reduced numbers of phenotypic HSCs, with an even more severe loss of long-term repopulating HSCs, likely reflecting the presence of non-HSCs within the phenotypic HSC compartment. Competitive transplantation experiments established that Flt3-ITD compromises HSCs through an extrinsically mediated mechanism of disrupting HSC-supporting bone marrow stromal cells, with reduced numbers of endothelial and mesenchymal stromal cells showing increased inflammation-associated gene expression. Tumor necrosis factor (TNF), a cell-extrinsic potent negative regulator of HSCs, was overexpressed in bone marrow niche cells from FLT3-ITD mice, and anti-TNF treatment partially rescued the HSC phenotype. These findings, which establish that Flt3-ITD–driven myeloproliferation results in cell-extrinsic suppression of the normal HSC reservoir, are of relevance for several aspects of acute myeloid leukemia biology.

1 November 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
WNWen Hao Neo
Wen Hao Neo
JLJun Feng Lim
Jun Feng Lim
RGRaelene Grumont
Raelene Grumont
SGSteve Gerondakis
Steve Gerondakis
ISI-Hsin Su
I-Hsin Su
The polycomb group protein Ezh2 is a histone methyltransferase that modifies chromatin structure to alter gene expression during embryonic development, lymphocyte activation, and tumorigenesis. The mechanism by which Ezh2 expression is regulated is not well defined. In the current study, we report that c-Rel is a critical activator of Ezh2 transcription in lymphoid cells. In activated primary murine B and T cells, plus human leukemia and multiple myeloma cell lines, recruitment of c-Rel to the first intron of the Ezh2 locus promoted Ezh2 mRNA expression. This up-regulation was abolished in activated c-Rel-deficient lymphocytes and by c-Rel knockdown in Jurkat T cells. Treatment of malignant cells with the c-Rel inhibitor pentoxifylline not only reduced c-Rel nuclear translocation and Ezh2 expression, but also enhanced their sensitivity to the Ezh2-specific drug, GSK126 through increased growth inhibition and cell death. In summary, our demonstration that c-Rel regulates Ezh2 expression in lymphocytes and malignant lymphoid cells reveals a novel transcriptional network in transformed lymphoid cells expressing high levels of Ezh2 that provides a molecular justification for combinatorial drug therapy.